<DOC>
	<DOCNO>NCT02511639</DOCNO>
	<brief_summary>The purpose study compare maintenance Aromatase Inhibitors ( AIs ) + everolimus Aromatase Inhibitors alone 1st line chemotherapy patient HR+ metastatic breast cancer .</brief_summary>
	<brief_title>Maintenance Aromatase Inhibitors ( AIs ) + Everolimus v AIs Hormone Receptor Positive Metastatic Breast Cancer Patients</brief_title>
	<detailed_description>The purpose study : - compare progression free survival ( PFS ) AIs/everolimus AIs administer maintenance therapy HR+ advance breast cancer patient disease control ( Complete Response ( CR ) , Partial Response ( PR ) Stable Disease ( SD ) ) 1st line chemotherapy . - To evaluate overall survival - To assess safety profile - To evaluate response rate</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>1 . &gt; 18 year old woman metastatic breast cancer 2 . Histological confirmation hormonereceptor positive ( define least 10 % estrogen receptor ( ER ) and/or progesterone receptor ( PgR ) positivity ) human epidermal growth factor receptor 2 ( HER2 ) negative ( score 01+ immunohistochemistry FISH negativity ) breast cancer 3 . Postmenopausal status 4 . One line chemotherapy metastatic disease ; patient must receive minimum 6 cycle chemotherapy order eligible , must obtain disease control ( CR PR od SD ) 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance status &lt; 2 6 . Adequate bone marrow coagulation function 7 . Adequate liver function 8 . Adequate renal function 9 . Fasting serum cholesterol ≤ 300 mg/dl 7.75 mmol/L fast triglyceride ≤ 2.5 × upper limit normal ( ULN ) . In case one threshold exceed , patient include initiation statin therapy lipid lower drug ( eg fibrates ) , mention value achieve 10 . Fasting glucose &lt; 1.5 × ULN 11 . Written inform consent obtain screening procedure accord local guideline . 1 . HER2overexpressing patient local laboratory testing ( immunohistochemistry 3+ stain situ hybridization positive ) 2 . Previous treatment mammalian target rapamycin ( mTOR ) inhibitors 3 . Known hypersensitivity mTOR inhibitor , e.g . sirolimus ( rapamycin ) 4 . More one chemotherapy line metastatic disease 5 . Treatment angiogenetic compound maintenance therapy ( eg . bevacizumab ) 6 . Radiotherapy within four week prior enrollment except case localize radiotherapy analgesic purpose lytic lesion risk fracture complete within two week prior enrollment . Patients must recover radiotherapy toxicity prior enrollment 7 . Symptomatic central nervous system metastases 8 . Patients known history HIV positivity 9 . Active , bleed diathesis , oral antivitamin K medication ( except low dose warfarin acetylsalicylic acid equivalent , long international normalize ratio ( INR ) ≤ 2.0 ) 10 . Any severe / uncontrolled medical condition : Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior enrollment , serious uncontrolled cardiac arrhythmia Uncontrolled diabetes define fast serum glucose &gt; 1.5 × ULN Acute chronic , active infectious disorder nonmalignant medical illness uncontrolled whose control may jeopardize complication study therapy Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) Significant symptomatic deterioration lung function . If clinically indicate , pulmonary function test include measure predict lung volume , diffusion capacity lung carbon monoxide ( DLco ) O2 saturation rest room air consider exclude restrictive pulmonary disease , pneumonitis pulmonary infiltrates . 11 . Patients test positive hepatitis B C ( patient test negative hepatitis B virus ( HBV ) DNA , HBsAg , HBcAb positive HBsAb prior history vaccination Hepatitis B eligible ) 12 . Patients treat drug recognize strong inhibitor inducer isoenzyme Cytochrome P3A ( Rifabutin , Rifampicin , Clarithromycin , Ketoconazole , Itraconazole , Voriconazole , Ritonavir , Telithromycin ) within last 5 day prior enrollment 13 . History noncompliance medical regimen 14 . Patients unwilling unable comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hormone receptor positive</keyword>
	<keyword>HER2 negative</keyword>
</DOC>